InnoSer News
The benefits of introducing Meso Scale Discovery technology to your preclinical research
Many methods to measure pharmacodynamic endpoints are currently available, for instance, enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Measuring these endpoints is a crucial step in...
A day in the life of InnoSer neurology study associate Teun van Nunen
To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
A day in the life of InnoSer data scientist Sander Klerk
To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
CONNECT: Connecting Cerebral Organoids to the Blood-Brain Barrier
The CONNECT project aims to develop a novel organoid-chip connecting the blood vasculature to the brain to mimic the blood-brain barrier (BBB). This complex 3D-model can be used to mimic aspects of drug delivery into the human brain, a key process that is often not...
A day in the life of InnoSer’s Intern Marketing Analysts Meilin Berkhoff & Amber Schonk
Meilin and Amber are both students of Leiden University completing their Masters in Biomedical Sciences Management. As part of their study requirements, Amber and Meilin are with us for a total of 6 months and will step into the role of marketing analysts. They...
TRANSCEND: developing a novel platform integrating organoid and humanized in vivo models for Parkinson’s Disease
The TRANSCEND project aims to tackle the current limitations of drug development for Parkinson’s Disease by the integration of an innovative in vitro brain organoid model and a humanized in vivo mouse model. This unique two-step platform supports InnoSer’s aspiration...
On a mission to bring smart science to patients: a new chapter in InnoSer history
As the InnoSer team, we are delighted to share the news – as of this week, we have a renewed vision and mission statement, as well as a renewed logo to accompany them. With these changes, we are ready more than ever not only for our continued growth and strong team...
How to bring innovation to the drug development space
Innovation is not only part of InnoSer’s name but is central to its activities. We believe, the solution for the continuously high drug attrition rates resides in addressing the problem already at the preclinical stages of drug development. More specifically, we aim...
Nano+ Project Ends With Promising Results
Currently with no known cure, Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. InnoSer has recently finished a project with promising results in understanding altered...
Interested In InnoSer’s Services?
Get in touch with us.
